Chemotherapy-induced amenorrhea and fertility in women undergoing adjuvant treatment for breast cancer

Cancer Control

Volumn 9, Issue 6, 2002, Pages 466-472

  Minton, Susan E ^a   Munster, Pamela N ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ESTRADIOL; FLUOROURACIL; GONADORELIN AGONIST; GOSERELIN; METHOTREXATE; TAMOXIFEN;

AMENORRHEA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; DOSE RESPONSE; ESTRADIOL BLOOD LEVEL; FEMALE; FEMALE INFERTILITY; HUMAN; MENOPAUSE; PREMENOPAUSE; PROGNOSIS; REVIEW;

EID: 0036863752     PISSN: 10732748     EISSN: None     Source Type: Journal    
DOI: 10.1177/107327480200900603     Document Type: Review

References (41)

1. Jemal A, Thomas A, Murray T, et al. Cancer statistics, 2002. CA Cancer J Clin. 2000;52:23-47.
2. Kalantaridou SN, Davis SR, Nelson LM. Premature ovarian failure. Endocrinol Metab Clin North Am. 1998;27:989-1006.
3. Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol. 1996;14:1718-1729.
4. Gelber S, Coates AS, Goldhirsch A, et al. Effect of pregnancy on overall survival after the diagnosis of early-stage breast cancer. J Clin Oncol. 2001;19:1671-1675.
5. Vegetti W, Marozzi A, Manfredini E, et al. Premature ovarian failure. Mol Cell Endocrinol. 2000;161:53-57.
6. Gradishar WJ, Schilsky RL. Ovarian function following radiation and chemotherapy for cancer. Semin Oncol. 1989;16:425-436.
7. Miller JJ 3rd, Williams GF, Leissring JC. Multiple late complications of therapy with cyclophosphamide, including ovarian destruction. Am J Med. 1971;50:530-535.
8. Schilsky RL, Lewis BJ, Sherins RJ, et al. Gonadal dysfunction in patients receiving chemotherapy for cancer. Ann Intern Med. 1980;93:109-114.
9. Warne GL, Fairley KF, Hobbs JB, et al. Cyclophosphamide-induced ovarian failure. N Engl J Med. 1973;289:1159-1162.
10. Goldhirsch A, Gelber RD, Castiglione M. The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients: The International Breast Cancer Study Group. Ann Oncol. 1990;1:183-188.
11. Polychemotherapy for early breast cancer: An overview of the randomised trials: Early Breast Cancer Trialists' Collaborative Group. Lancet. 1998;352:930-942.
12. Levine MN, Bramwell VH, Pritchard KI, et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1998;16:2651-2658.
13. Nabholtz J, Pienkowski T, Mackey J, et al. Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer (BC) patients: Interim analysis of the BCIRG 001 study. Proc Annu Meet Am Soc Clin Oncol. 2002:141. Abstract.
14. Goldhirsch A, Gelber RD, Yothers G, et al. Adjuvant therapy for very young women with breast cancer: Need for tailored treatments. J Natl Cancer Inst Monogr. 2001;30:44-51.
15. Padmanabhan N, Howell A, Rubens RD. Mechanism of action of adjuvant chemotherapy in early breast cancer. Lancet. 1986;2:411-414.
16. Valagussa P, Moliterni A, Zambetti M, et al. Long-term sequelae from adjuvant chemotherapy: Recent results. Cancer Res. 1993; 127:247-255.
17. Hortobagyi GN, Buzdar AU, Marcus CE, et al. Immediate and long-term toxicity of adjuvant chemotherapy regimens containing doxorubicin in trials at M.D. Anderson Hospital and Tumor Institute. J Natl Cancer Inst Monogr. 1986;1:105-109.
18. Harris JR, Lippman ME, Morrow M, et al. Diseases of the Breast. 2nd Ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2000.
19. Meirow D. Reproduction post-chemotherapy in young cancer patients. Mol Cell Endocrinol. 2000;169:123-131.
20. Damewood MD, Grochow LB. Prospects for fertility after chemotherapy or radiation for neoplastic disease. Fertil Steril. 1986; 45:443-459.
21. Sobrinho LG, Levine RA, DeConti RC. Amenorrhea in patients with Hodgkin's disease treated with antineoplastic agents. Am J Obstet Gynecol. 1971;109:135-139.
22. Blumenfeld Z. Ovarian rescue/protection from chemotherapeutic agents. J Soc Gynecol Investig. 2001;8:S60-S64.
23. Blumenfeld Z. Preservation of fertility and ovarian function and minimalization of chemotherapy associated gonadotoxicity and premature ovarian failure: The role of inhibin-A and -B as markers. Mol Cell Endocrinol. 2002;187:93-105.
24. Poikonen P, Saarto T, Elomaa I, et al. Prognostic effect of amenorrhoea and elevated serum gonadotropin levels induced by adjuvant chemotherapy in premenopausal node-positive breast cancer patients. Eur J Cancer. 2000;36:43-48.
25. A randomized trial of adjuvant combination chemotherapy with or without prednisone in premenopausal breast cancer patients with metastases in one to three axillary lymph nodes. Ludwig Breast Cancer Study Group. Cancer Res. 1985;45:4454-4459.
26. Chemotherapy with or without oophorectomy in high-risk premenopausal patients with operable breast cancer. Ludwig Breast Cancer Study Group. J Clin Oncol. 1985;3:1059-1067.
27. Combination adjuvant chemotherapy for node-positive breast cancer. Inadequacy of a single perioperative cycle. The Ludwig Breast Cancer Study Group. N Engl J Med. 1988;319:677-683.
28. Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer. The Ludwig Breast Cancer Study Group. N Engl J Med. 1989;320:491-496.
29. Duration and reintroduction of adjuvant chemotherapy for node-positive premenopausal breast cancer patients. International Breast Cancer Study Group. J Clin Oncol. 1996;14:1885-1894.
30. Aebi S, Gelber S, Castiglione-Gertsch M, et al. Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? Lancet. 2000;355:1869-1874.
31. Klijn JG, Blamey RW, Boccardo F, et al. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: A meta-analysis of four randomized trials. J Clin Oncol. 2001;19:343-353.
32. Houghton J, Baum M, Rutqvist LE, et al. The ZIPP trial of adjuvant zoladex in premenopausal patients with early breast cancer: An update at five years. Proc Annu Meet Am Soc Clin Oncol. 2000:359. Abstract.
33. Davidson NE. Combined endocrine therapy for breast cancer: New life for an old idea? J Natl Cancer Inst. 2000;92:859-860.
34. Braverman AS, Sawhney H, Tendler A, et al. Pre-menopausal serum estradiol (E2) levels may persist after chemotherapy (CT)-induced amenorrhea in breast cancer (BC). Proc Annu Meet Am Soc Clin Oncol. 2002:164. Abstract.
35. Waxman J. Preserving fertility in Hodgkin's disease. Baillieres Clin Haematol. 1987;1:185-190.
36. Recchia F, Sica G, De Filippis S, et al. Goserelin as ovarian protection in the adjuvant treatment of premenopausal breast cancer: A phase II pilot study. Anticancer Drugs. 2002;13:417-424.
37. Carroll J, Whittingham DG, Wood MJ, et al. Extra-ovarian production of mature viable mouse oocytes from frozen primary follicles. J Reprod Fertil. 1990;90:321-327.
38. Carroll J, Wood MJ, Whittingham DG. Normal fertilization and development of frozen-thawed mouse oocytes: Protective action of certain macromolecules. Biol Reprod. 1993;48:606-612.
39. Gosden RG, Baird DT, Wade JC, et al. Restoration of fertility to oophorectomized sheep by ovarian autografts stored at -196 degrees C. Hum Reprod. 1994;9:597-603.
40. Blumenfeld Z, Haim N. Prevention of gonadal damage during cytotoxic therapy. Ann Med. 1997;29:199-206.
41. Revel A, Laufer N. Protecting female fertility from cancer therapy. Mol Cell Endocrinol. 2002;187:83-91.